Liputan6.com, jakarta – Sinopharm, the Chinese National Pharmaceutical Group, is increasingly demonstrating its fangs in the global arena. Sinofarm is managed directly by the State Commission for Supervision of Assets and the Advisory Administration in the State Council of China.
Liputan6.com, together with several journalists from the Asia-Pacific region, who are members of the Chinese International Press Center program (CIPCC), had the opportunity to visit Sinopharm on Thursday, July 3, 2025.
Synopharm has a complete industrial network, which includes research and development (R&D), production, logistics and distribution, retail networks, health care services, engineering technologies, exhibitions, international enterprises, for the development of traditional Chinese medicine.
“The core of business synoframes fully covers the entire chain of medical industry. Some labels attached to synopharms include, we are the third largest pharmaceutical distributor in the world and the largest in Asia, ”said the General International Sinopharma Manager in the Central and Eastern European branches, Tong Sin.
He also explained about the scale and large ambitions of this company. In the presentation for almost 25 minutes, Tong said that Sinopharm had a strategic expansion plan for Belarus and Indonesia.
According to Tongga, Synopharm is ready to build hospitals, logistics centers and pharmaceutical factories with local partners. They offer a comprehensive solution, starting from technical and economic justification, design, construction, instruments, training and management. “We are also looking for investment opportunities in Belarus and Indonesia to expand our presence,” he said.
Currently, Sinofarm has collaborated with international partners on five continents. In total, cooperation was created with more than 195 countries, in about 100 famous world companies of pharmaceutical and medical companies, for international organizations. “We already have representative offices in Asia, including Indonesia, India, Japan, Korea, Macau and the Middle East.
